MPG.eBooks - Description: Daclizumab (Zinbryta)

Cover Image

Read Now

Daclizumab (Zinbryta)

The objective of this systematic review is to examine the beneficial and harmful effects of Daclizumab (DAC) subcutaneously (SC) in the treatment of active relapsing-remitting multiple sclerosis (RRMS) in adult patients

Bibliographic Details
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	[Ottawa, Ontario] Canadian Agency for Drugs and Technologies in Health July 2017, 2017
Series:	CADTH Common drug review, clinical review report
Subjects:	Drug Evaluation Multiple Sclerosis, Relapsing-remitting / Drug Therapy Canada Daclizumab / Adverse Effects Treatment Outcome Daclizumab / Therapeutic Use
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK535191
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The objective of this systematic review is to examine the beneficial and harmful effects of Daclizumab (DAC) subcutaneously (SC) in the treatment of active relapsing-remitting multiple sclerosis (RRMS) in adult patients
Physical Description:	1 PDF file (ix, 113 pages) illustrations